摘要
目的系统评价他汀类药物联用非诺贝特的安全性。方法检索1981至2013年Medline、Cochrane Library、Web of Knowledge和中国知网数据库中的随机对照临床试验，采用RevMan5．0软件对所纳入的数据进行荟萃分析。共检索2184篇相关文献，有26篇文献入选，26项随机对照临床研究共纳入9494例患者。结果他汀类药物联合非诺贝特组转氨酶升高的风险明显高于单药他汀组（OR1．67，95％CI1．22—2．30，P〈0．05）。肌酸激酶升高（OR0．86，95％CI0．62—1．20，P〉0．05）、肌肉不良反应（OR 0．98，95％CI0．88—1．09，P〉0．05）、肝功异常和肌肉不良反应导致退出的发生率两组问差异无统计学意义。常规剂量他汀类药物联合非诺贝特的安全性与总剂量他汀类药物联合非诺贝特相似。结论他汀类药物联用非诺贝特具有良好的安全性和耐受性，不增加肌肉不良反应的风险。联合用药时要定期检测转氨酶，防止发生肝功能异常。
Objective The aim of this study was to assess the safety of fenofibrate-statin combination therapy. Methods Medline, Coehrane Library, Web of Knowledge and CNKI were searched for 2184 randomized controlled trims. Finally, twenty-six studies with a total of 9494 participants were included in this analysis. Results Compared with statins group, the fenofibrate-statin group had significantly higher incidence of aminotransferase elevations （ OR 1.67,95% CI 1.22 - 2. 30 ,P 〈 0. 05 ）. The two groups had identical incidence of creatin kinase elevations （ OR 0. 86,95% CI 0. 62 - 1.20, P 〉 0. 05 ） , muscle- associated adverse events （ OR 0. 98,95% CI0. 88 - 1.09 ,P 〉 0. 05 ） and withdrawals due to hepatotoxicity or muscle toxicity. The safety of fenofibrate ＋ standard-dose statin regimens were similar to those in fenofibrate-statin group. Conclusion Combined fenofibrate-statin treatment is generally safe and well tolerated, liver function should be monitored before and during and after therapy.
出处
《中华心血管病杂志》
CAS
CSCD
北大核心
2013年第12期1063-1068,共6页
Chinese Journal of Cardiology
基金
国家自然科学基金（NSFC81070179,30570712）
关键词
降血脂药
可重复性
结果
META分析
Antilipemie agents
Reprodueility of results
Meta-analysis
